Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus gemcitabine and cisplatin as first-line treatment for unresectable advanced biliary tract cancer
ChiCTR2400089867Phase 2Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Sep 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, gemcitabine and cisplatin in biliary cancer, sponsored by Second Hospital of Lanzhou University. Primary endpoint: Objective response rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
cadonilimabgemcitabinecisplatin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2400089867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089867.